In this issue:
Rituximab for interstitial lung disease associated with antisynthetase syndrome
Switching from adalimumab to adalimumab biosimilar SB5 in RA
Long-term safety and efficacy of belimumab in SLE
Efficacy and safety of biosimilar infliximab and originator infliximab in active RA
Adalimumab in early-onset, chronic, JIA-associated anterior uveitis
Risk of malignancy with paediatric TNF-inhibitor exposure
Ixekizumab every 2 weeks for moderate-to-severe plaque psoriasis
Dupilumab in adults with atopic dermatitis Ixekizumab impact on cardiovascular parameters
Long-term efficacy and safety of ustekinumab in CD
Please login below to download this issue (PDF)